Objectives: To explore the VagCD toxin-antitoxin (TA) systems encoded on plasmids in multiresistant Klebsiella pneumoniae strains.
Introduction
Toxin-antitoxin (TA) systems have been discovered initially on plasmids, and more recently on chromosomes, as systems ensuring plasmid stability in bacterial populations. The first TA system, CcdA/CcdB, was discovered in 1983 on the IncF plasmid of Escherichia coli 1 and it is now known that TA systems are widely spread in the prokaryotic world. These systems are mostly composed of two elements: a stable toxin and its labile antitoxin. Three main types of TA systems have been described: while the toxins are always proteins, the antitoxins may be either proteins interacting directly with the toxin (type II TA system), or non-coding RNAs inhibiting translation of the toxin-encoding mRNA (type I) 2 or noncoding RNAs binding the toxin itself (type III). 3 The most abundant and explored TA systems are of type II. These systems code mostly for toxins inhibiting translation and rarely for toxins inhibiting replication. Translation inhibition leads to bacterial growth arrest, while replication inhibition could result in splits in the DNA strands and in cell death. Plasmid-encoded TA systems are often known as post-segregational killing systems, 4 working then as addiction systems killing daughter cells that did not receive the plasmid during cell division. The effects of chromosome-encoded TA systems have been recently described: they could play a role in the formation of dormant bacteria in response to stressful conditions (e.g. antibiotic treatment, amino acid starvation), as is the case of the HipA/HipB system. 5 Paradoxically, this would improve cell survival. However, some TA systems, e.g. MazEF in E. coli K12, seem to be specifically involved in programmed cell death in stressful conditions. 6 The VapBC family is by far the largest of the TA systems. The VapC toxins belong to the PilT N-terminal (PIN) domain family of proteins. The PIN domain contains about 130 amino acids and consists of an endoribonuclease, characterized by a quartet of negatively charged acidic residues coordinating Mg 2! ions in a potential catalytic site. 7 The VapC toxins belong to the endoribonucleases, such as toxins of the families RelBE and MazEF. A VapBC family system, the TA system VagCD, was found to be encoded on a virulence plasmid of Salmonella enterica serovar Dublin in 1992, 9 with the report concluding that the vagCD operon could prevent cell division before a plasmid replication cycle was completed. It was then demonstrated that a VapBC family locus, mvpAT, enabled stabilization of the Shigella flexnerii plasmid pMYSH6000 by post-segregational killing systems. 10 More recent studies found that the chromosome-encoded toxins VapC of Leptospira interrogans and the S. enterica serovar Typhimurium LT2 and the plasmid-encoded toxin MvpT of S. flexneri were able to cleave specifically the initiator tRNA fMet and thus to inhibit translation.
11,12
Klebsiella pneumoniae plays a major role in antibiotic resistance dissemination, and the genes of several type I and type II TA systems (Hok/Sok, PemK/PemI, CcdA/CcdB) have been previously identified on resistance plasmids carried by this bacterium. Intriguingly, VagCD-type systems are named in GenBank annotations of K. pneumoniae plasmid sequences, but their genetic diversity and possible functions in this species or other Enterobacteriaceae have not been investigated. It was our aim to study VagCD further in multiresistant K. pneumoniae strains. Here, we report the identification of two distinct types of this TA system and describe their bactericidal potential as conferred by plasmid constructs replicating in K. pneumoniae, E. coli and other Enterobacteriaceae.
Materials and methods

Bacterial strains and media
Bacterial strains (Table S1 , available as Supplementary data at JAC Online) were grown in LB broth at 37 C. When required, the growth medium was supplemented with 250 lg/mL ticarcillin and/or 50 lg/mL spectinomycin. Transcription from AraC-regulated promoters was induced by the addition of 0.2% arabinose, or inhibited by the addition of 0.5% glucose.
Plasmid constructions
All plasmid constructions (Table S1 ) were obtained in E. coli TOP10. pBAD43 contains the arabinose-inducible pBAD promoter, and a gene for spectinomycin resistance, as previously described. 13 pUC19 contains the Plac promoter and a gene for ampicillin/ticarcillin resistance. The vagC1 antitoxin gene was obtained by PCR using genomic DNA from K. pneumoniae strain S9 (from the laboratory collection; Table S1 ) and primers VagC-BamHI_F and VagC-EcoRI_R (Table S2 ). The PCR product was digested with BamHI and EcoRI and ligated into pUC19 to obtain pVagC1. The vagC2 antitoxinencoding gene was amplified by PCR using genomic DNA from K. pneumoniae strain S30 (Table S1 ) and primers VagC-gpe2-BamHI_F and VagC-gpe2-EcoRI_R (Table S2 ). The PCR product was digested with BamHI and EcoRI and ligated into pUC19 to obtain pVagC2. The vagD1 toxinencoding gene was synthesized by PCR using K. pneumoniae strain S9, and primers VagD-EcoRI_F and VagD-XbaI_R (Table S2 ). The PCR product was digested with EcoRI and XbaI and ligated into pBAD43 to obtain pVagD1. The vagD2 toxin-encoding DNA was amplified by PCR using K. pneumoniae strain S30 and primers VagD-gpe2-EcoRI_F and VagD-gpe2-KpnI_R (Table S2 ). The PCR product was digested with EcoRI and KpnI and ligated into pBAD43 to obtain pVagD2. All constructions were verified by sequencing.
In silico analysis
The in silico analysis was done with GenBank BLAST (http://blast.ncbi.nlm. nih.gov/). The VagD annotated toxins were searched among 78 sequenced K. pneumoniae plasmids .50 kb, to focus on self-transferable plasmids. The ClustalW2 program (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used for multiple sequence alignments. A phylogenetic tree was constructed with the software Mega5.2 (http://www.megasoftware.net/) using the neighbor-joining method and bootstrapping (1000 replications).
Epidemiological analysis
Two pairs of primers were designed for multiplex PCR: VagCD FIIK for VagCD1 and VagCD Gp2 for VagCD2, respectively (Table S2 ). The set of resistant strains of K. pneumoniae (n " 63) included 44 strains with plasmids carrying ESBL genes (SHV, TEM, CTX-M-3 or CTX-M-15), 14 with plasmidborne ampC genes and 12 with carbapenemase genes (VIM, OXA-48 or NDM). The set of all plasmids have been previously typed for Inc major groups by PRaseT (plasmid relaxase gene typing) and by simplex PCR for the IncR group. 14, 15 The entire collection was screened and the amplified vagCD sequences were determined, using the PCR primers, and finally aligned and compared to evaluate gene variability.
Evaluation of the toxic and antitoxic potency of the VagCD components
E. coli TOP10 was transformed with pUC19, pBAD43, pVagC1, pVagC2, pVagD1 or pVagD2. The double recombinants pVagD1-pVagC1, pVagD1-pUC19, pVagD2-pVagC2 and pVagD2-pUC19 were also prepared.
Toxicity tests on agar plates
To evaluate the toxic potency of the VagD proteins, the pVagD1 and pVagD2 clones were plated on glucose-or arabinose-containing agar plates (for repression and expression of the toxin, respectively). Once the toxic potential was confirmed, the same clones were made competent and further transformed with a pUC19 recombinant plasmid expressing the putative VagC antitoxin. The double recombinants obtained were then plated on arabinose and their growth was compared to that of the simple recombinants. In each experiment, selective antibiotic pressure was maintained with ticarcillin or spectinomycin to eliminate every cell that could have lost the recombinant plasmid during culture. Replica plating was used in E. coli to distinguish a bactericidal from a bacteriostatic effect of the toxin ( Figure S1a ). K. pneumoniae SS1, Klebsiella oxytoca 75004, Citrobacter freundii 18922, Citrobacter koseri 19577 and Enterobacter cloacae ME-STA were transformed with pVagD1, pVagD2, pVagD1 ! pVagC1, or pVagD1 ! pUC19 and tested in agar plates.
Growth on microscope slides
Clones carrying the pVagD1 or pVagD2 plasmids were deposited on slides in a thin layer of agarose (1%) (low melting point agarose; Promega, Madison, WI, USA) containing either 0.5% glucose or 0.2% arabinose ! 0.5% glycerol. Slides were incubated at 37 C and observed microscopically at 45, 90 and 180 min (Olympus BX51, %10 eyepiece, %60 lens; Olympus XM10 camera).
Growth kinetics experiments E. coli TOP10, K. pneumoniae SS1, C. freundii 18922 and E. cloacae ME-STA transformed with pVagD1, pVagD2, pVagD1 ! pVagC1, or pVagD1 ! pUC19 were tested. In addition, the E. coli TOP10 double recombinants pVagD2 ! pVagC2 and pVadD2 ! pUC19 were tested. To start the experiment, cells were diluted to a turbidity equivalent to that of a 0.5 McFarland standard in 10 mL of LB broth supplemented with 0.5% glucose (to repress vagD) and the appropriate antibiotics allowing maintenance of plasmids. After 90 min of growth at 37 C with shaking, the exponential phase was reached and 0.5% arabinose was added to induce vagD. To determine the relative number of surviving cells, serial dilutions of the cultures were plated on 0.5% glucose-supplemented agar, at t " 0 and 30, 90, 150 and 210 min Klebsiella pneumoniae VagCD system JAC after induction of toxin synthesis. Plates were incubated at 37 C for 24 h before counting of the colonies. Replica plating on 0.5% glucosesupplemented agar plates was used to determine the viability of the strains ( Figure S1b ). Experiments were repeated twice with the E. coli and K. pneumoniae strains producing VagCD1.
Results
In silico analysis by similarity search allowed us to identify 12 (15%) complete VagCD systems encoded on 78 sequenced K. pneumoniae plasmids (.50 kb). Two phylogenic trees (VagC and VagD) were built using the deduced amino acid sequences (Figure 1a and b) . Considering the plasmid's incompatibility groups, for both trees, two groups of toxins (VagD1, VagD2) and two groups of antitoxins (VagC1, VagC2) were clearly distinguished. For the IncFIIK group, constituted of six IncFIIK plasmids, the toxins VagD1, as the antitoxins VagC1, were found to be similar with 100% identity. In contrast, for the second group constituted of three IncR plasmids, two Inc FIB plasmids (pKP187 and pLVPK) and one IncN plasmid, a greater diversity was observed within the VagC2 antitoxins (98.7%-100% identity) and within the VagD2 toxins (95.65%-100% identity) (Figure 1a and b) .
The two types of VagD toxins (D1 and D2) were compared to those described in the literature. The corresponding protein sequences exhibited identities ranging from 29.6% to 43.9% (Table 1) , and a PIN domain typical of the VapC-type RNases could be identified in VagD1 and VagD2 (Figure 2 ).
In the epidemiological study carried out on a set of 63 K. pneumoniae clinical isolates, a VagCD TA system was found in 11 isolates (17.5%) ( Table 2) , confirming the prevalence found in the in silico analysis. These 11 isolates correspond to 6 of 44 of the plasmids carrying ESBL genes, 3 of 14 of those carrying ampC genes and 2 of 12 of those carrying carbapenemase genes. Finally, the five VagCD1 types were harboured by IncFIIK plasmids and the six VagCD2 types by IncR plasmid, supporting the hypothesis of a close correlation between the incompatibility groups and the type of VagCD TA systems.
The functionality of the plasmid-encoded VagCD1 and VagCD2 systems was assessed by expressing in E. coli the putative toxins (VagD1 and VagD2) and antitoxins (VagC1 and C2) from recombinant plasmids. First, clones of E. coli transformed with the plasmids pBAD43, pVagD1 or pVagD2 were plated on medium containing arabinose or glucose, to induce or repress VagD gene expression. In the presence of arabinose, expression of vagD1 or vagD2 resulted in the absence of bacterial growth, confirming the toxic potency of the proteins VagD1 and VagD2 in E. coli ( Figure  S2 ). The same experiment was carried out with the double recombinants pVagD1-pVagC1, pVagD1-pUC19, pVagD2-pVagC2 and pVagD2-pUC19. Cells expressing both the toxin and its cognate antitoxin showed a normal growth phenotype, demonstrating that VagCD1 and VagCD2 are functional TA systems in E. coli. Considering the strong similarity (86%) between the toxin genes vagD1 and vagD2, intersystem double recombinants pVagD1-pVagC2 and pVagD2-pVagC1 were also tested and displayed a normal growth phenotype as well ( Figure S3 ). This showed that the VagC1 and VagC2 antitoxins could both neutralize the VagD1 or VagD2 toxins.
Considering that K. pneumoniae is frequently involved in interspecies conjugation events in vivo, we further investigated the two VagCD systems by evaluating their functionality in other species of Enterobacteriaceae. Thus, the experiments described above in E. coli have been reproduced with the TA system VagCD1 in K. pneumoniae, K. oxytoca, C. koseri, C. freundii and E. cloacae (Table S1) . For each of the tested strains, the toxicity of VagD1 and the functionality of the VagCD1 system were confirmed ( Figure S4 ).
To determine whether the toxic effect of VagD1 and VagD2 is bactericidal or bacteriostatic, the clones E. coli pVagD1 and pVagD2 were first submitted to a replica plating experiment, the results of which were compared to those of a control with kanamycin as the bactericidal agent ( Figure S5 ). With both toxins, colonies were observed after replica plating on glucose agar from a plate containing arabinose, with a growth pattern identical to that observed on the initial plates ( Figure S5b) , an observation that is in favour of a bacteriostatic effect.
Microscopic observations on E. coli pVagD1 cells were then made to see if morphological modifications occurred after the induction of VagD1 expression ( Figure S6 ). When the toxin gene was expressed (arabinose induction), cell division was impaired after 3 h and fewer and longer cells were observed (close to 5 lm) in Duprilot et al. Figure 2 . Alignment of the amino acid sequences of some VapC family toxins. Boxed residues indicate the perfect matching of: 1, conserved threonine; 2, four acidic residues responsible for coordinating metal ions in the catalytic site; and 3, cysteine involved in dimerization. Conserved residues between VagD1 and VagD2 are highlighted. Only the strains harbouring a VagCD system (n " 11) are listed.
Klebsiella pneumoniae VagCD system
JAC which apparently no initiation of division occurred ( Figure S6b) , whereas when the toxin gene was repressed (glucose repression), we noticed normal growth ( Figure S6b ) similar to that of the negative control ( Figure S6a ). Cell growth experiments were then conducted in liquid medium to evaluate bacterial growth after induction of the VagD1 toxin with arabinose. As shown in Figure 3 , an increase in turbidity over time was observed for the negative control E. coli pBAD43 and the double recombinant E. coli pVagD1-pVagC1. In contrast, after a similar induction in E. coli pVagD1-pUC19, we observed a plateau in the turbidity curve, suggesting that bacteria were not lysed 5 h after induction of VagD1. We also examined if the cells growing in liquid medium remained viable by determining changes in cfu over time (Figure 4) . With E. coli, a 4 log decrease in the number of cfu was observed for the strains expressing VagD1 or VagD2, meaning that about 10 4 bacteria/mL survived. By contrast, the number of cfu remained constant when the toxin was neutralized by the antitoxin in the double recombinant pVagD-pVagC (Figure 4a ). When these experiments were conducted in K. pneumoniae, C. freundii and E. cloacae with the VagCD1 TA system, results similar to those obtained with E. coli were obtained: a 4 log decrease was observed for K. pneumoniae recombinants producing the toxin VagD1 (pVagD1-pUC19) (Figure 4b ). The effect of VagD1 was less pronounced on the growth of C. freundii and E. cloacae than of E. coli and K. pneumoniae (2.5-3 log decreases in cfu counts) (data not shown). All double recombinants pVagD1-pVagC1 obtained in K. pneumoniae, C. freundii and E. cloacae showed growth curves nearly identical to those of the untransformed clinical isolates, which demonstrate the functionality of the TA system VagCD1 in these species.
Finally, following these growth experiments, after the arabinose induction (see the 'Growth kinetics experiments' section, and Figure S1b ), we examined if transformed cells expressing the VagD1 toxin were dead or could be in a dormant state. To identify viable cells not forming macroscopic colonies (dormant cells) on the first agar culture plates, a replicate of these was performed on glucose agar plates. After 24 h of incubation, no regrowth was observed for E. coli pVagD1-pUC19, E. coli pVagD2-pUC19 and K. pneumoniae pVagD1-pUC19. 
Discussion
We have focused this study on the TA system VagCD encoded on resistance plasmids of K. pneumoniae, a species that plays a major role in the dissemination of antibiotic resistance and provide new data on this system still little explored in Enterobacteriaceae. In GenBank, 15.4% of the sequenced K. pneumoniae plasmids studied and 17.5% of our resistant K. pneumoniae isolates were found to harbour the VagCD TA system. The prevalence of VagCD has been studied previously in E. coli producing ESBLs, particularly CTX-M-15. Mnif et al. 16, 17 reported that 14.4% and 12.2% of the E. coli strains producing TEM, SHV or CTX-M in a French and a Tunisian collection, respectively, harboured the TA system VagCD. Doumith et al. 18 described a significant association between VagCD and the plasmids encoding CTX-M-15 in the clone ST131. Accordingly, in the present study we detected the VagCD system in 15% of sequenced plasmids from K. pneumoniae and in 17.5% of our resistant K. pneumoniae collection. Moreover, this system has been reported recently to be encoded on K. pneumoniae IncA/C plasmids carrying the carbapenemase genes NDM-1 or VIM-1 in Canada and South Africa, reinforcing the idea of a widespread distribution of VagCD in resistant Enterobacteriaceae.
19,20 Finally, we noticed a possible correlation between the genotype of the TA system VagCD and the Inc group of the carrier plasmid, VagCD1 being encoded on FIIk plasmids and VagCD2 on R and FIB plasmids. This correlation suggests a coevolution between the plasmids and their VagCD TA systems, similar to that previously observed for the PemKI TA system and the IncL/M and IncF plasmids (G. Arlet, unpublished results).
In the present study using toxicity tests in agar medium, we have confirmed that VagCD1 and VagCD2 of K. pneumoniae are functional TA systems in E. coli and K. pneumoniae. TA systems of the same family, whether chromosome-or plasmid-encoded, have been previously proved to be functional, such as VagD of the virulence plasmid of Salmonella Dublin described in 1992 by Pullinger and Lax 9 and the chromosome-encoded toxin VapC of Salmonella Typhimurium LT2 and the toxin MvpT of plasmid pMYSH6000 of S. flexnerii reported in 2011. 12 Furthermore, we have shown that the interaction between the antitoxins VagC1 and VagC2 and the toxins VagD1 and VagD2, respectively, is not specific as each antitoxin could efficiently neutralize both toxins, a result suggesting a recent divergence of the two VagCD TA subtypes. We also demonstrated the functionality of the K. pneumoniae VagCD TA systems in other Enterobacteriaceae, such as C. freundii and E. cloacae, K. oxytoca and C. koseri. Such a broad host range could augment the capacity of K. pneumoniae to transfer multidrug resistance-determining plasmids by enhancing the maintenance of these plasmids after conjugational transfer, even in the absence of antibiotic selective pressure.
The mode of action of VagCD was not studied here. However, one mechanism of action was elucidated in Enterobacteriaceae for TA systems related to VagCD: VapC in Salmonella Typhimurium LT2 and VapC (MvpT) in S. flexnerii have been shown to have RNase activity specifically cleaving the initiator tRNA fMet between the anticodon stem and loop, which results in translation inhibition. 12 The same mechanism has been described for VapC of L. interrogans. RNase activities of VapC toxins from Haemophilus influenzae and Mycobacterium tuberculosis have also been reported. 21, 22 Recently, the VapC20 toxin of M. tuberculosis was demonstrated to cleave the sarcin-ricin loop of the ribosomal 23S RNA. 23 It is therefore likely that the VagD toxins of K. pneumoniae have a similar mode of action based on ribonuclease activity and translation inhibition. At the physiological level, we have tried to describe the effects of the VagD toxins on bacteria by carrying out various growth experiments with E. coli cells transformed with pVagD1 or pVagD1-pUC19. The lengthening of cells observed after expression of VagD1 was previously highlighted by Pullinger and Lax 9 in strain G19 of Salmonella Dublin, supporting a bacteriostatic mode of action of the toxin. Similarly, Winther and Gerdes 12 previously reported the reversible and bacteriostatic action of TA systems of the superfamily VapBC of Salmonella Typhimurium LT2, and of the plasmid pMYSH6000 of S. flexnerii. The results we obtained for the K. pneumoniae VagCD system were not fully concordant as the toxins VagD1 and VagD2 had a bactericidal effect entailing a 4 log decrease in the bacterial population when the toxins were produced while 10 4 bacteria/mL were able to survive toxin induction. However, the experimental set-ups were quite different, as Winther and Gerdes 12 worked with a different strain (E. coli MG1655) and induced the vapB antitoxin gene expression (cloned under an IPTG-inducible promoter) during the experiment, while we used E. coli TOP10, and did not induce the vagC antitoxin gene expression to neutralize the toxin. The latter population is probably composed of persister cells, as previously suggested. 24, 25 The nature of the toxic action of several TA systems has been debated for years. For example, the toxin MazF was first described as a mediator of programmed bacterial cell death in stressful conditions, 26 and later as an inducer of a stationary state, which does not lead to cell death. 27 Later, it was shown that MazF toxicity depends on culture conditions and time of exposure before antitoxin addition. 28 If one considers the possible bivalent behaviour of VagCD in K. pneumoniae, it is tempting to speculate that the TA system can ensure an equilibrium between cell death and persistence, thus optimizing the odds of surviving and maintaining plasmids in stressful environmental conditions.
In conclusion, this is the first known report of plasmid-encoded VagCD TA systems in K. pneumoniae that comprise the subgroups VagCD1 and VagCD2. Their analysis has revealed that they are functional not only in K. pneumoniae but also in E. coli, K. oxytoca, C. freundii, C. koseri and E. cloacae. We therefore assume that they provide an important mechanism contributing to the spread and maintenance of many plasmids in pathogens around the world.
